Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has completed its previously announced registered direct offering. The company raised $15.3 million in gross proceeds through the sale of 13,939,331 shares of common stock at $1.10 per share.
The net proceeds, after deducting approximately $0.8 million in placement agent fees and other offering expenses, will be used for working capital and general corporate purposes. Canaccord Genuity served as the sole placement agent for the offering.
Lucid Diagnostics (Nasdaq: LUCD), un'azienda di diagnostica medica per la prevenzione del cancro in fase commerciale e filiale di PAVmed Inc. (Nasdaq: PAVM), ha completato l'offerta diretta registrata precedentemente annunciata. L'azienda ha raccolto 15,3 milioni di dollari in proventi lordi attraverso la vendita di 13.939.331 azioni di azioni ordinarie a 1,10 dollari per azione.
I proventi netti, dopo aver dedotto circa 0,8 milioni di dollari in commissioni per l'agente di collocamento e altre spese dell'offerta, saranno utilizzati per il capitale circolante e per scopi aziendali generali. Canaccord Genuity ha svolto il ruolo di unico agente di collocamento per l'offerta.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico en etapa comercial para la prevención del cáncer y subsidiaria de PAVmed Inc. (Nasdaq: PAVM), ha completado su oferta directa registrada previamente anunciada. La empresa recaudó 15,3 millones de dólares en ingresos brutos a través de la venta de 13.939.331 acciones de acciones ordinarias a 1,10 dólares por acción.
Los ingresos netos, después de deducir aproximadamente 0,8 millones de dólares en comisiones del agente de colocación y otros gastos de la oferta, se utilizarán para capital de trabajo y propósitos corporativos generales. Canaccord Genuity actuó como el único agente de colocación para la oferta.
Lucid Diagnostics (Nasdaq: LUCD), 상업 단계의 암 예방 의료 진단 회사이자 PAVmed Inc. (Nasdaq: PAVM)의 자회사인 이 회사는 이전에 발표된 등록된 직접 공모를 완료했습니다. 이 회사는 1,393,9331주의 보통주를 주당 1.10달러에 판매하여 1,530만 달러의 총 수익을 올렸습니다.
약 80만 달러의 배치 에이전트 수수료 및 기타 공모 비용을 공제한 후의 순수익은 운영 자본 및 일반 기업 목적에 사용될 것입니다. Canaccord Genuity는 이 공모의 단독 배치 에이전트로 활동했습니다.
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostic médical en phase commerciale pour la prévention du cancer et filiale de PAVmed Inc. (Nasdaq: PAVM), a terminé son offre directe enregistrée précédemment annoncée. L'entreprise a levé 15,3 millions de dollars en recettes brutes grâce à la vente de 13.939.331 actions ordinaires à 1,10 dollar par action.
Les produits nets, après déduction d'environ 0,8 million de dollars de frais d'agent de placement et d'autres frais d'offre, seront utilisés pour le fonds de roulement et des fins corporatives générales. Canaccord Genuity a agi en tant qu'agent de placement exclusif pour l'offre.
Lucid Diagnostics (Nasdaq: LUCD), ein kommerzielles Unternehmen für medizinische Diagnostik zur Krebsprävention und Tochtergesellschaft von PAVmed Inc. (Nasdaq: PAVM), hat seine zuvor angekündigte registrierte Direktplatzierung abgeschlossen. Das Unternehmen hat 15,3 Millionen Dollar an Bruttoerlösen durch den Verkauf von 13.939.331 Aktien zu einem Preis von 1,10 Dollar pro Aktie erzielt.
Die Nettomittel, nach Abzug von etwa 0,8 Millionen Dollar an Gebühren für den Platzierungsagenten und anderen Angebotskosten, werden für Betriebskapital und allgemeine Unternehmenszwecke verwendet. Canaccord Genuity fungierte als alleiniger Platzierungsagent für das Angebot.
- Secured $15.3M in additional funding
- Successfully completed registered direct offering
- Working capital strengthened for operations
- Share dilution with 13.9M new shares issued
- Offering price of $1.10 indicates significant discount to market
- Additional $0.8M in fees and expenses reducing net proceeds
The gross proceeds to the Company from this offering are approximately
The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
The securities described above were offered pursuant to a registration statement on Form S-3 (File No. 333-268560), which was declared effective by the Securities and Exchange Commission on December 6, 2022. A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus included in the registration statement may be obtained by contacting Canaccord Genuity LLC, Attention: Syndicate Department, One Post Office Square, Suite 3000,
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering-302393766.html
SOURCE Lucid Diagnostics
FAQ
How much did Lucid Diagnostics (LUCD) raise in its March 2025 registered direct offering?
What is the price per share for LUCD's March 2025 stock offering?
How will Lucid Diagnostics use the proceeds from its 2025 offering?
What are the placement agent fees for LUCD's March 2025 offering?
